Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on ejection fraction reduction, myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.
Vincenzo Quagliariello(Cancer Institute (WIA)), Nicola Maurea(Cancer Institute (WIA)), Vienna Giordano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesca Izzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), I Giacobbe(University of Campania "Luigi Vanvitelli"), Massimiliano Berretta(University of Messina), Alessandro Inno(Ospedale Sacro Cuore Don Calabria), Matteo Barbato(University of Milan), Martina Iovine(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesca Bruzzese(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppe Palma(University of Brescia), Maria Laura Canale(Ospedale Versilia), Irma Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Antonio Luciano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Raffaele Arianna(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Fabrizio Maurea(Federico II University Hospital)
Cited by 3
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
|Critical Reviews in Oncology/Hematology|2019|164
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108
Resveratrol in Cancer Patients: From Bench to Bedside
|International Journal of Molecular Sciences|2020|105